Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used with chemotherapy for the treatment of metastatic non-small cell lung cancer. It is an antineoplastic antibody that strengthens T-cell responses, including anti-tumor responses, by blocking the binding of PD-1 to PD-L1 ligands. Its article lists common side effects including anemia, raised liver enzymes, rash, high blood fat and sugar levels, low sodium, potassium and calcium, protein in urine, abdominal pain, tiredness, joint pain, reduced sensation and an underactive thyroid. It was approved for medical use in China in December 2021, in the European Union in July 2024 and in the United Kingdom in October 2024.
Facts
Classification
Approval Status ATC ClassL: Antineoplastic and Immunomodulating Agents 2 First Approved / Isolated Year Sources
1. Sugemalimab (Wikipedia)
Lead paragraphQuote, Lead paragraph
Sugemalimab was approved for medical use in China in December 2021
2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATC/DDD Index entries named Sugemalimab
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATC/DDD Index entry; ATC class derived from cited code L01FF11 (main group L)Quote, ATC/DDD Index entry; ATC class derived from cited code L01FF11 (main group L)
L01FF11 sugemalimab
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.